Compare Canadian National Railway Co. (CNI) vs Pfizer Inc (PFE) Price & Performance

Canadian National Railway (CNI) trades at $125.14, down 1.15% with a bearish technical signal. The company reported strong Q2 2026 results with EPS of $1.50 beating estimates by 7.9% and raised full-year guidance, driven by record grain volumes and improved operational efficiency. Fundamentals show solid profitability with 26.92% net margin and 22.02% ROE, though valuation multiples appear elevated with P/E of 22.62. Recent news highlights continued infrastructure investment and customer growth projects exceeding $2 billion in 2025.

CNI presents a mixed outlook with strong operational execution offset by valuation concerns. The 21.8% upside to consensus price target of $152.38 offers potential, but rising debt levels and competitive pressures pose risks. Analyst sentiment is cautious with 60.79% hold ratings, suggesting waiting for clearer evidence of sustained earnings growth before committing new capital.

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.